In silico-based screening for druggable targets highlighted FDA-approved carvedilol as an inhibitor of vascular cell adhesion molecule 1 (VCAM1) synthesis as a promising candidate for IPF treatment (Figure 1A). Here, VCAM1 is linked to idiopathic pulmonary fibrosis.